Levotofisopam is the S-enantiomer of racemic tofisopam Monotherapy with levotofisopam led to clinically meaningful reduction of Serum Uric Acid (SUA) in patients with hyperuricemia and gout. Treatment was generally well tolerated with 23% of the patients experiencing gout flare. Increased fractional excretion of uric acid suggests that levotofisopam reduces SUA primarily through uricosuric activity. These results support further studies to investigate the potential role of levotofisopam for in the treatment of hyperuricemia in gout. Levotofisopam prescribed outside the United States for such stress-related disorders as anxiety, functional gastrointestinal disorders, and symptoms of menopause. Thought to affect autonomic tone via interaction with subcortical 2,3-benzodiazepine receptors, levotofisopam has shown promise in animal models of stress-related gastrointestinal dysfunction and menopause. We conducted a trial of levotofisopam in healthy human volunteers.Also was showed, that levotofisopam significantly reduced both objective and subjective measures of hot flash frequency in postmenopausal women within 7 days of treatment.